216 related articles for article (PubMed ID: 10910028)
1. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
Otto C; Geiss HC; Donner MG; Parhofer KG; Schwandt P
Ther Apher; 2000 Jun; 4(3):244-8. PubMed ID: 10910028
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis.
Geiss HC; Parhofer KG; Schwandt P
J Intern Med; 1999 Jan; 245(1):47-55. PubMed ID: 10095816
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
[TBL] [Abstract][Full Text] [Related]
4. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR
J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129
[TBL] [Abstract][Full Text] [Related]
5. Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia.
Empen K; Geiss HC; Lehrke M; Otto C; Schwandt P; Parhofer KG
Nutr Metab Cardiovasc Dis; 2003 Apr; 13(2):87-92. PubMed ID: 12929621
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment.
Banyai S; Banyai M; Falger J; Jansen M; Alt E; Derfler K; Koppensteiner R
Atherosclerosis; 2001 Dec; 159(2):513-9. PubMed ID: 11730833
[TBL] [Abstract][Full Text] [Related]
7. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H
Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703
[TBL] [Abstract][Full Text] [Related]
8. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.
Schmaldienst S; Banyai S; Stulnig TM; Heinz G; Jansen M; Hörl WH; Derfler K
Atherosclerosis; 2000 Aug; 151(2):493-9. PubMed ID: 10924726
[TBL] [Abstract][Full Text] [Related]
10. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
[TBL] [Abstract][Full Text] [Related]
11. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
12. The effect of simvastatin therapy on hemorheological profile in coronary heart desease (CHD) patients.
Muravyov AV; Yakusevich VV; Surovaya L; Petrochenko A
Clin Hemorheol Microcirc; 2004; 31(4):251-6. PubMed ID: 15567894
[TBL] [Abstract][Full Text] [Related]
13. Effects of direct adsorption of lipoproteins apheresis on lipoproteins, low-density lipoprotein subtypes, and hemorheology in hypercholesterolemic patients with coronary artery disease.
Otto C; Geiss HC; Laubach E; Schwandt P
Ther Apher; 2002 Apr; 6(2):130-5. PubMed ID: 11982953
[TBL] [Abstract][Full Text] [Related]
14. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
[TBL] [Abstract][Full Text] [Related]
15. [Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Szapáry L; Horváth B; Márton Z; Fehér G; Tóth K; Komoly S
Orv Hetil; 2008 Jun; 149(24):1117-23. PubMed ID: 18539578
[TBL] [Abstract][Full Text] [Related]
16. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
März W; Wollschläger H; Klein G; Neiss A; Wehling M
Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
[TBL] [Abstract][Full Text] [Related]
17. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Bo M; Nicolello MT; Fiandra U; Mercadante G; Piliego T; Fabris F
Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):17-24. PubMed ID: 11383320
[TBL] [Abstract][Full Text] [Related]
18. Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
Simons LA
Aust N Z J Med; 1998 Jun; 28(3):327-33. PubMed ID: 9673745
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
[TBL] [Abstract][Full Text] [Related]
20. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
